Alexander D. Borowsky

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity

  Journal of Clinical Investigation · 2026-03-17

• Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network

  Breast Cancer Research and Treatment · 2026-01-28

• Autostaining Immune Multiplex Immunohistochemistry Panels and Imaging Analysis

  Methods in molecular biology · 2026-01-01

• WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and DesignPreprint

  Research Square · 2025-12-15

• Risk-Based vs Annual Breast Cancer Screening

  JAMA · 2025-12-12 · 34 citations

• Germline Pathogenic Variants Among Women Without a History of Breast Cancer

  JAMA Internal Medicine · 2025-12-12 · 2 citations

• Spatial immunophenotyping of PD1 and PDL1 in tumor cells and microenvironment of nodal follicular T helper cell lymphoma

  Blood · 2025-11-03

• WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and DesignPreprint

  npj Breast Cancer · 2025-10-05 · 1 citations

• Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerPreprint

  medRxiv · 2025-08-27

• Roche Digital Pathology Dx whole slide imaging system is comparable to traditional microscopy for primary diagnosis in surgical pathology

  American Journal of Clinical Pathology · 2025-06-10 · 3 citations

• Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial

  JCO Precision Oncology · 2025-06-01 · 5 citations

• Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).

  Journal of Clinical Oncology · 2025-05-28

• Gene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts.

  Journal of Clinical Oncology · 2025-05-28

• I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).

  Journal of Clinical Oncology · 2025-05-28

• Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.

  Journal of Clinical Oncology · 2025-05-28 · 3 citations

• Nonlinear progression during the occult transition establishes cancer lethality

  Disease Models & Mechanisms · 2025-03-01 · 2 citations

• A Multicenter Study to Evaluate Diagnostic Accuracy by Pathologists Using the Aperio GT 450 DX in Local and Remote Viewing Stations

  Archives of Pathology & Laboratory Medicine · 2025-02-13 · 2 citations

• Adaptive selection of p53 mutation metaplastic phenotypes in estrogen-independent progression of ER+ tumors: A mechanism for acquired resistance to hormonal therapyPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-02-06

• Uncovering the role of oncogenic <i>HER2</i> variants as drivers of pancreatic cancer.

  Journal of Clinical Oncology · 2025-01-27

• Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ

  JAMA Oncology · 2025-01-16 · 21 citations